Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses

被引:225
作者
Costa, Luis A. [1 ]
Eiro, Noemi [1 ]
Fraile, Maria [1 ]
Gonzalez, Luis O. [1 ,2 ]
Saa, Jorge [1 ]
Garcia-Portabella, Pablo [1 ]
Vega, Belen [1 ]
Schneider, Jose [3 ]
Vizoso, Francisco J. [1 ]
机构
[1] Fdn Hosp Jove, Unidad Invest, Avda Eduardo Castro 161, Gijon 33920, Asturias, Spain
[2] Fdn Hosp Jove, Dept Anat Pathol, Gijon, Spain
[3] Univ Valladolid, Dept Obstet & Gynecol, Valladolid, Spain
关键词
Regenerative medicine; Aging diseases; Diabetes; Lupus; Secretome; Conditioned medium; Extracellular vesicles; Exosomes; ADIPOSE-DERIVED STEM; HUMAN BONE-MARROW; EXPRESSING INTERFERON-BETA; UMBILICAL-CORD BLOOD; FREE LYSATE INHIBIT; LOW-OXYGEN TENSION; STROMAL CELLS; IN-VITRO; PROGENITOR CELLS; GROWTH-FACTOR;
D O I
10.1007/s00018-020-03600-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mesenchymal stem cells (MSC) are present in all organs and tissues. Several studies have shown the therapeutic potential effect of MSC or their derived products. However, the functional heterogeneity of MSC constitutes an important barrier for transferring these capabilities to the clinic. MSC heterogeneity depends on their origin (biological niche) or the conditions of potential donors (age, diseases or unknown factors). It is accepted that many culture conditions of the artificial niche to which they are subjected, such as O(2)tension, substrate and extracellular matrix cues, inflammatory stimuli or genetic manipulations can influence their resulting phenotype. Therefore, to attain a more personalized and precise medicine, a correct selection of MSC is mandatory, based on their functional potential, as well as the need to integrate all the existing information to achieve an optimal improvement of MSC features in the artificial niche.
引用
收藏
页码:447 / 467
页数:21
相关论文
共 258 条
[51]   Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317
[52]   Modeling Physiological Events in 2D vs. 3D Cell Culture [J].
Duval, Kayla ;
Grover, Hannah ;
Han, Li-Hsin ;
Mou, Yongchao ;
Pegoraro, Adrian F. ;
Fredberg, Jeffery ;
Chen, Zi .
PHYSIOLOGY, 2017, 32 (04) :266-277
[53]   Three-Dimensional Cell Culture Systems and Their Applications in Drug Discovery and Cell-Based Biosensors [J].
Edmondson, Rasheena ;
Broglie, Jessica Jenkins ;
Adcock, Audrey F. ;
Yang, Liju .
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2014, 12 (04) :207-218
[54]   Angiogenic properties of aged adipose derived mesenchymal stem cells after hypoxic conditioning [J].
Efimenko, Anastasia ;
Starostina, Ekaterina ;
Kalinina, Natalia ;
Stolzing, Alexandra .
JOURNAL OF TRANSLATIONAL MEDICINE, 2011, 9
[55]   Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells [J].
Eiro, Noemi ;
Sendon-Lago, Juan ;
Seoane, Samuel ;
Bermudez, Maria A. ;
Lamelas, Maria Luz ;
Garcia-Caballero, Tomas ;
Schneider, Jose ;
Perez-Fernandez, Roman ;
Vizoso, Francisco J. .
ONCOTARGET, 2014, 5 (21) :10692-10708
[56]   Human Mesenchymal Stromal Cells from Different Sources Diverge in Their Expression of Cell Surface Proteins and Display Distinct Differentiation Patterns [J].
Elahi, Kourosch C. ;
Klein, Gerd ;
Avci-Adali, Meltem ;
Sievert, Karl D. ;
MacNeil, Sheila ;
Aicher, Wilhelm K. .
STEM CELLS INTERNATIONAL, 2016, 2016
[57]   Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy [J].
Eliopoulos, Nicoletta ;
Francois, Moira ;
Boivin, Marie-Noelle ;
Martineau, Daniel ;
Galipeau, Jacques .
CANCER RESEARCH, 2008, 68 (12) :4810-4818
[58]   Mesenchymal progenitor cells in human umbilical cord blood [J].
Erices, A ;
Conget, P ;
Minguell, JJ .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (01) :235-242
[59]   Overexpression of phosphoinositide-3-kinase class II alpha enhances mesenchymal stem cell survival in infarcted myocardium [J].
Eun, Lucy Youngmin ;
Song, Byeong-Wook ;
Cha, Min-Ji ;
Song, Heesang ;
Kim, Il-Kwon ;
Choi, Eunmi ;
Chang, Woochul ;
Lim, Soyeon ;
Choi, Eun Ju ;
Ham, Onju ;
Lee, Se-Yeon ;
Byun, Ki Hyun ;
Jang, Yangsoo ;
Hwang, Ki-Chul .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 402 (02) :272-279
[60]   Transplantation with survivin-engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction [J].
Fan, Lin ;
Lin, Chaogui ;
Zhuo, Shuangmu ;
Chen, Lianglong ;
Liu, Nan ;
Luo, Yukun ;
Fang, Jun ;
Huang, Zhengrong ;
Lin, Yunling ;
Chen, Jianxin .
EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (11) :1023-1030